Decline of Maternal Neutralizing Antibody Against Enterovirus Type 71 (EV71) in Young Infants in Northern Taiwan  by Luo, S.T. et al.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e299
46.020
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gapore
Background: Little is currently known about the
immunopathogenesis of dengue virus infection. However,
the complex interaction of host immune responses during
dengue virus infection has important implications on the
clinical outcome of patients. The role of Th genes during
dengue virus infection is poorly deﬁned.
Methods: In this project, we determine which genes are
differentially regulated in dengue type 2 virus-infected cell
lines (HepG2 -hepatocytes, K562 - myelogenous leukaemia
cell line and Jurkat - T cells). We used real-time PCR to
proﬁle the expression of 84 genes related to the three
classes of helper T cells: Th1, Th2 and Th3. This array
includes cytokine and chemokine genes representative of
Th1, Th2 and Th3 cells, transcriptional factors that regulate
the expression of these cytokines as well as genes involved
in the antimicrobial humoral response.
Results: The susceptibilities of the three cell lines to
dengue type 2 virus were evident by detection of viral
antigen and virus growth curve. Majority of the Th genes
that are differentially regulated in all the three cell lines
infected with dengue virus. However, Jurkat and K562 cells
showed more common regulation as compared to HepG2
cells probably because both of them are leukocytes. Among
the differentially regulated genes, TLR6 was signiﬁcantly
regulated in both dengue type 2 virus-infected K562 cells
and Jurkat cells. Semi-quantitative PCR and Western detec-
tion were performed to conﬁrm the up-regulation of TLR6.
High level of IL-6 expression was also detected from K562
cells and Jurkat cells.
Conclusion: K562 and Jurkat cells are permissive to
dengue type 2 virus infection. TLR 6 is up-regulated which in
turn leads to upregulation of IL-6 during dengue virus infec-
tion. This may have implications in the immunopathogenesis
of dengue virus biology.
doi:10.1016/j.ijid.2008.05.801
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Background: The spread of H5N1 virus in humans has
highlighted the threat of worldwide pandemic. T-705 is
a novel antiviral agent for treatment of inﬂuenza infec-
tion containing avian ﬂu. The compound has been found
to possess a potent and selective inhibitory activity against
broad spectrum inﬂuenza viruses including H5N1 strains
both in vitro and in vivo. T-705 is converted to the ribo-
syl phosphates by host cellular enzymes, and the ribosyl
triphosphate inhibits viral RNA polymerase selectively. The
antiviral mechanism of T-705 differs from currently pre-
scribed drugs involving the neuraminidase inhibitors and the
viral M2 protein ion channel inhibitors. Thus, T-705 may be
valuable for patients suffering from uncomplicated seasonal
inﬂuenza as well as complicated seasonal and/or avian ﬂu
infection.
Method: Phase 1 studies of T-705a, a code name for
oral formulations of T-705, have been conducted in healthy
volunteers in Japan. The single dose study was designed
as a randomized, double-blind, placebo-controlled, dose-
ascending trial in 48 men. The multiple dose for 7 days study
was designed as a randomized, double-blinded, placebo-
controlled, dose-ascending trial in 24 men.
Result: In the single dose of 30 to 1600mg, T-705 was
characterised by rapid absorption and elimination into urine
as T-705M1, the major metabolite and hydroxide of T-
705. Cmax increased approximately proportionally to dose.
AUCinf, however, increased more than proportionally to
dose. In the ﬁrst group of the multiple dose study, the
plasma T-705 concentration increased progressively due to
inhibition of metabolic enzyme. Plasma T-705 concentra-
tion was controlled up to 1200mg/day by modifying the
dosage and administration. No serious adverse events were
reported.
Conclusion: Single and multiple oral dose of T-705 were
well-tolerated. These results indicate deserving to progress
next studies for patients with inﬂuenza infection.
doi:10.1016/j.ijid.2008.05.802
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Background: Clinical spectrum of EV71 infection ranges
from mild hand-foot-mouth disease (HFMD) to severe
cases with central nervous system and cardiopulmonary
involvements. In 1998, Taiwan suffered a nation-wide EV71
epidemic with 405 reported severe cases and 78 fatal cases.
Since then, EV71 has been endemic in Taiwan and develop-
ment of EV71 vaccines has become a national priority. This
cohort study was designed to understand decline of maternal
EV71 neutralizing antibody titers and age-speciﬁc incidence
rates of EV71 infection in Taiwan, which will be crucial for
designing efﬁcacy trials of EV71 vaccines.
Methods: This study is a prospective longitudinal cohort
study and was approved by the Institutional Review Boards
in CGMH and NHRI. Pregnant women having prenatal exams
were invited to participate. Sera were collected from par-
ticipating mother/baby for measuring EV71 neutralizing
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antibody titers in the following schedules: last trimester
from mother, umbilical cord blood at birth, and children at
6, 12, 24, 36, and 48 months old.
Results: The recruitment started in June 2006. By Jan-
uary 2008, 201 longitudinal serum specimens collected from
mothers, neonates, and 6-month-old babies (one mother
delivered twins) have been measured with EV71 neutraliz-
ing antibody titers. The seropositive rates (percentage of
antibody titer ≥ 1:8) in mothers, neonates, and 6-month-
old babies were 61%(122/201), 46%(93/202), and 0%(0/202),
respectively. Geometric mean titers (95% conﬁdence inter-
vals) of serum EV71 antibody in mothers and neonates were
10.2 (8.7, 11.5) and 8.5 (7.4, 9.7), respectively.
Conclusions: In northern Taiwan, only 46% of neonates
have protective antibody against EV71 and these maternal
antibody titers have declined to undetectable level (<8) by
6 months of age. Historical data in the 1998 epidemic also
showed that infants under 1 year old had the highest risk
of severe EV71 infection. Therefore, development of EV71
vaccines in Taiwan should target infants under 6 months
old.
doi:10.1016/j.ijid.2008.05.803
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The global polio eradication program recommends the
use of massive vaccination campaigns with live vaccine
through National Immunization Days (NIDs) to displace the
wild virus from the community. Immunodeﬁcient patients
may be indirectly infected and become chronic excre-
tors and potential reservoirs of polioviruses, a concern for
the post eradication era. This prospective study aimed to
assess the risk of community-acquired infection of immun-
odeﬁcient patients following NIDs, the dynamics of viral
excretion and the genetic variation of excreted viruses.
Sixteen children with various primary immunodeﬁciencies,
who did not receive the vaccine during the campaign, were
investigated. Stool samples were collected weekly, shortly
after the NIDs, during at least three months and processed
for viral isolation. Isolates were characterized by three
intratypic differenciation methods and partial sequencing
of the VP1/2A region. Polioviruses were detected in 4 out
of 16 patients (serotype1 in 3 patients and serotype3 in one
patient). Sequencing revealed more than 99% homology with
homotypic Sabin strains suggesting recent infection. Dura-
tion of viral excretion ranged from 1 to 7 weeks. Nine out
of eleven isolates from the 3 polio1-infected patients dis-
closed a Non Sabin Like phenotype by ELISA and had recurent
mutations within or close to the neutralizing antigenic sites.
The risk of secondary infection in immunodeﬁcient patients
is within the range reported for the general population.
Although none of the four infected patients developed
prolonged viral excretion, particular viral variants were
selected and may be of epidemiological signiﬁcance.
doi:10.1016/j.ijid.2008.05.804
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The increasing prevalence of inﬂuenza viruses resis-
tant to antiviral drugs such as amantadine and oseltamivir
undermines our ability to defend against future inﬂuenza
pandemics. There is an urgent need to develop novel
antiviral agents which are robust and offer broad-spectrum
protection against the ever changing inﬂuenza viruses. The
objective of this study is to evaluate the in vivo antivi-
ral efﬁcacy nucleic acid-based immunomodulators such as
Poly ICLC (synthetic ds RNA) and oligonucleotides con-
taining unmethylated CpG using a mouse lethal infection
model with inﬂuenza A/PR/8/34 (H1N1) and/or with the
highly pathogenic avian inﬂuenza H5N1 (HPAI) viruses.
Groups of BALB/c mice were pre-treated intranasally with
1 or 2 doses of liposome-encapsulated Poly ICLC (LE-Poly
ICLC, 20g/dose/mouse) or with CpG (5g/dose/mouse)
oligonucleotides. At various times post pre-treatment, the
animals were challenged intranasally with multiple doses of
inﬂuenza A/PR/8/34 or with HPAI viruses, and survival rates
of control and pre-treated mice were compared at day 14
post infection. Pre-treatment with liposome-encapsulated
Poly ICLC provided complete protection against 10 LD50
inﬂuenzaA/PR/8/34 and 1 LD50 dose of HPIA virus. When
the challenge dose of HPIA was increased to 4 LD50, the pro-
tection provided by LE-Poly ICLC was 63—75% (p < 0.001 vs
control), with all control mice succumbed to the infection.
Pre-treatment with CpG oligonucleotides provided complete
protection to mice against 5 LD50 inﬂuenza A/PR/8/34. The
window of protection (the time interval between drug pre-
treatment and virus challenge) was 21 days for LE-Poly ICLC
and 4 days for CpG oligonucleotides, respectively. RT-PCR
analyses of mouse lung tissues from LE-Poly ICLC treated
mice showed activation of toll-like receptor-3 pathway, and
induction of cytokines including IL 1-, -, IFN-, TNF-,
among others. Collectively, these results suggest that LE-
Poly ICLC can provide broad-spectrum protection and may
have an important role in protecting against avian or sea-
sonal inﬂuenza infections.
doi:10.1016/j.ijid.2008.05.805
